Published in Women's Health Weekly, October 2nd, 2008
"Patients and Methods Patients who relapsed after adjuvant anthracyclines were randomly assigned to gemcitabine, 1,250 mg/m(2) days 1 and 8 plus paclitaxel, 175 mg/m2 on day 1; or, to paclitaxel at same dose on day 1 (both arms administered every 21 days, unblinded). The primary end point was overall survival ( OS) and secondary end points were time to progression...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly